Squamous cell carcinoma of the lung is a specific type of lung cancer that develops when the thin, flat cells lining the airways begin to grow abnormally. This cancer typically starts in the central part of the lungs and is strongly linked to smoking. Treatment approaches depend on how advanced the disease is when discovered, and researchers continue to explore new ways to help patients live longer and more comfortably.

How Treatment Choices Are Made for Squamous Cell Lung Cancer

When someone receives a diagnosis of squamous cell carcinoma of the lung, the treatment plan is never one-size-fits-all. Doctors carefully consider several important factors before recommending specific therapies. The stage of the cancer—meaning how large the tumor is and whether it has spread beyond the lungs—plays the most critical role in determining which treatments will be most helpful.^[2]

Other factors that influence treatment decisions include the patient’s overall health, age, and ability to tolerate certain procedures or medications. Some patients may have other medical conditions that make certain treatments less suitable. The presence of specific molecular markers (unique characteristics of the cancer cells) can also guide treatment choices, particularly for advanced disease.^[7]

The goal of treatment varies depending on the stage at diagnosis. For early-stage cancers, the aim is often to remove the tumor completely and prevent it from coming back. When the cancer has spread to other parts of the body, treatment focuses on controlling the disease, managing symptoms, and maintaining quality of life for as long as possible.^[15]

Medical teams that treat lung cancer typically include several specialists working together. This might include lung doctors (pulmonologists), cancer doctors (oncologists), surgeons, radiation specialists, and nurses who specialize in cancer care. This team approach helps ensure that patients receive comprehensive care tailored to their specific situation.^[2]

Standard Treatment Approaches

Surgery for Early-Stage Disease

Surgery remains the preferred treatment for patients with early-stage squamous cell carcinoma of the lung when the cancer has not spread beyond the lungs. The surgical approach depends on the size and location of the tumor. In many cases, surgeons remove the part of the lung containing the tumor along with some surrounding healthy tissue to ensure all cancer cells are removed.^[15]

There are different types of lung surgery depending on how much tissue needs to be removed. A lobectomy removes one of the lung’s lobes (sections), while a pneumonectomy involves removing an entire lung. These procedures are major surgeries that require general anesthesia and typically several days of hospital recovery. Not all patients are suitable candidates for surgery—doctors must consider lung function, heart health, and overall physical condition before recommending this approach.^[5]

After surgery, many patients receive additional treatment called adjuvant therapy to reduce the risk of cancer returning. This might include chemotherapy or other medications designed to eliminate any remaining cancer cells that cannot be seen or detected by imaging tests.^[15]

Radiation Therapy

Radiation therapy uses high-energy beams to destroy cancer cells. For patients who cannot undergo surgery due to other health problems or tumor location, radiation serves as an important alternative treatment option. It can also be used after surgery to target any cancer cells that might remain in the chest area.^[15]

The radiation is carefully aimed at the tumor site to minimize damage to surrounding healthy tissue. Treatment is usually given in multiple sessions over several weeks, with each session lasting only a few minutes. Patients do not feel the radiation during treatment, though they may experience side effects afterward. Common side effects include fatigue, skin changes in the treated area (similar to sunburn), difficulty swallowing if the esophagus is near the treatment field, and shortness of breath.^[6]

Advanced radiation techniques allow doctors to deliver precise doses to the tumor while protecting healthy lung tissue. This precision helps reduce side effects and allows for more effective treatment.^[15]

Chemotherapy

Chemotherapy involves using medications to kill cancer cells throughout the body. For squamous cell carcinoma of the lung, chemotherapy typically uses combinations of drugs rather than a single medication. The standard approach involves platinum-based chemotherapy, which means one of the drugs in the combination contains platinum.^[14]

For many years, platinum-based doublet chemotherapy has been the backbone of treatment for advanced squamous cell lung cancer. This means two different chemotherapy drugs are given together, with one being a platinum compound like cisplatin or carboplatin. The response rate to these traditional combinations has been around 20%, with survival times averaging about eight months.^[14]

Chemotherapy can be given at different stages of treatment. Neoadjuvant chemotherapy is given before surgery to shrink tumors and make them easier to remove. Adjuvant chemotherapy is given after surgery to eliminate remaining cancer cells. For advanced disease, chemotherapy serves as the main treatment to control cancer growth and relieve symptoms.^[15]

Chemotherapy affects rapidly dividing cells throughout the body, which explains its side effects. Cancer cells divide quickly, but so do cells in the hair follicles, digestive tract lining, and bone marrow. This leads to common side effects including hair loss, nausea and vomiting, diarrhea, loss of appetite, increased risk of infections, easy bruising or bleeding, and fatigue. Many of these side effects can be managed with additional medications, and most resolve after treatment ends.^[6]

Combined Approaches

Many patients with locally advanced squamous cell carcinoma benefit from combining chemotherapy and radiation therapy. When given together, these treatments work in complementary ways—chemotherapy attacks cancer cells throughout the body while radiation targets the main tumor and nearby lymph nodes. Studies have shown that this combined approach can be more effective than either treatment alone for certain stages of disease.^[15]

The timing and sequence of these treatments must be carefully planned. Sometimes they are given at the same time (concurrent chemoradiation), while other times they may be given one after another (sequential treatment). Concurrent treatment tends to be more effective but also causes more intense side effects, so doctors must balance effectiveness with tolerability for each individual patient.^[15]

Emerging Treatments in Clinical Trials

Immunotherapy Advances

Immunotherapy represents one of the most promising developments in treating squamous cell carcinoma of the lung. These treatments work by helping the patient’s own immune system recognize and attack cancer cells. Unlike chemotherapy, which directly kills rapidly dividing cells, immunotherapy essentially trains the immune system to do the job.^[6]

One important type of immunotherapy involves blocking proteins called PD-1 (programmed death receptor-1) or PD-L1 (programmed death ligand-1). Cancer cells sometimes use these proteins as a disguise to hide from the immune system. Drugs called checkpoint inhibitors remove this disguise, allowing immune cells to recognize and destroy the cancer. These medications are given through intravenous infusion, typically every few weeks.^[15]

In 2022, regulatory authorities approved the use of nivolumab, a checkpoint inhibitor, in combination with chemotherapy before surgery for patients with resectable squamous cell lung cancer. This approval was based on clinical trial results showing that patients who received this combination had better outcomes than those receiving chemotherapy alone. The trial included patients with larger tumors (at least 4 centimeters) or cancer that had spread to nearby lymph nodes.^[15]

Immunotherapy can cause different side effects compared to chemotherapy. Because these drugs activate the immune system, they can sometimes cause the immune system to attack healthy tissues. This leads to immune-related side effects that can affect various organs including the lungs, liver, intestines, or skin. Common side effects include fatigue, rash, diarrhea, and inflammation of various organs. While these effects can be serious, they are often manageable with appropriate monitoring and treatment.^[15]

Targeted Therapy Development

Targeted therapy uses drugs designed to attack specific molecular abnormalities within cancer cells. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies zero in on particular proteins or genetic changes that help cancer cells grow and survive. Researchers continue to study various targeted agents in clinical trials for squamous cell carcinoma of the lung.^[15]

Molecular testing of tumor samples can identify whether specific genetic changes are present that might respond to targeted drugs. This testing looks for mutations (changes in genes) or other abnormalities that drive cancer growth. When such changes are found, doctors may recommend targeted drugs as part of a clinical trial.^[7]

Some targeted therapies under investigation focus on blocking signals that tell cancer cells to divide and grow. Others target the blood supply that feeds tumors, cutting off nutrients and oxygen the cancer needs to survive. Clinical trials test these approaches at different stages—early trials focus on safety, while later trials compare new treatments to standard options to determine if they offer better outcomes.^[15]

Understanding Clinical Trial Phases

Clinical trials follow a structured process to ensure new treatments are safe and effective. Phase I trials are the first tests in humans, focusing primarily on safety. Researchers determine the appropriate dose and identify side effects in a small group of participants. Phase II trials involve more patients and evaluate whether the treatment shows promise in shrinking tumors or slowing disease progression.^[7]

Phase III trials are large studies that compare a new treatment directly against the current standard treatment. These trials provide the evidence needed for regulatory approval of new drugs. They may involve hundreds or even thousands of patients at multiple medical centers across different countries. Participants are typically assigned randomly to receive either the new treatment or the standard treatment, allowing researchers to determine which approach works better.^[7]

Patients considering clinical trials should discuss the potential benefits and risks with their medical team. Trials offer access to promising new treatments before they become widely available, but they also involve uncertainties. Not all experimental treatments prove to be effective, and some may cause unexpected side effects. However, clinical trials are essential for advancing cancer treatment and have led to many of the therapies now considered standard of care.^[7]

Research in Treatment Combinations

Researchers are actively exploring combinations of different treatment approaches to improve outcomes for patients with squamous cell carcinoma of the lung. One area of investigation involves combining immunotherapy with chemotherapy. Studies have shown that this combination can improve survival compared to chemotherapy alone for some patients with advanced disease.^[14]

The concept behind combination therapy is that different treatments attack cancer through different mechanisms. When used together, they may be more effective than either treatment alone. However, combining treatments also requires careful attention to side effects, as patients receive multiple medications that each have their own potential complications.^[15]

Clinical trials testing new combinations are conducted at medical centers around the world, including in the United States, Europe, and other regions. Eligibility for these trials depends on factors such as the stage of cancer, previous treatments received, overall health status, and specific characteristics of the tumor.^[7]

Most Common Treatment Methods

• Surgery
  • Lobectomy to remove affected lung lobe for early-stage disease
  • Pneumonectomy to remove entire lung when necessary
  • Primary option for stage I through IIIA cancer when patient is suitable candidate
  • Often followed by additional therapy to prevent recurrence
• Radiation Therapy
  • Uses high-energy beams to destroy cancer cells
  • Alternative for patients who cannot undergo surgery
  • Can be combined with chemotherapy for locally advanced disease
  • May be used after surgery to eliminate remaining cancer cells
• Chemotherapy
  • Platinum-based doublet chemotherapy as standard approach
  • Combinations typically include cisplatin or carboplatin with another drug
  • Can be given before surgery (neoadjuvant), after surgery (adjuvant), or as main treatment
  • Response rates around 20% with median survival about 8 months for advanced disease
• Immunotherapy
  • Checkpoint inhibitors such as nivolumab that block PD-1/PD-L1 proteins
  • Approved in combination with chemotherapy before surgery for resectable disease
  • Works by activating patient’s immune system to fight cancer
  • Represents major advance in treatment options
• Combined Approaches
  • Concurrent or sequential chemotherapy and radiation for locally advanced cancer
  • Immunotherapy combined with chemotherapy showing improved outcomes
  • Multidisciplinary team approach involving various specialists